Presbyterian is offering monoclonal antibody therapy for the treatment of COVID-19 non-hospitalized patients, who have mild to moderate disease, and who are at high risk of progressing to severe COVID-19 and/or hospitalization. Bamlanivimab/Etesevimab and Casirivimab/Imdevimab are monoclonal antibody therapies under FDA Emergency Use Authorization. Current availability and prevalence of coronavirus variants will determine which monoclonal antibody is offered.
This therapy is available only through a provider referral. If you are a patient and are interested in this therapy, you will need to contact your provider’s office.
Which patients are eligible for this therapy?
Adult and pediatric patients with positive results of direct SARS-CoV-2 viral testing (PCR or antigen testing) who are 12 years of age and older, weigh at least 40 kg, and who are at
high risk for progressing to severe COVID-19 and/or hospitalization.
The monoclonal antibody therapy should be administered as soon as possible after a positive COVID-19 test and
within 10 days of symptom onset. Patients are not eligible for treatment if >10 days from symptom onset. Treatment generally takes two to three hours in one single session. Not all infusion locations may be able to facilitate monoclonal antibody pediatric infusions; please call your local site to confirm.
must meet at least one
high risk criterion for treatment eligibility:
Older age (for example ≥65 years of age)
Obesity or overweight
Adult: BMI ≥25
Age 12-17: BMI ≥85th percentile for their age and gender based on
CDC growth charts
Chronic kidney disease (CKD)
Immunosuppressive disease or immunosuppressive treatment
Cardiovascular disease (including congenital heart disease) or hypertension
Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-tosevere], interstitial lung disease, cystic fibrosis and pulmonary hypertension)
Sickle cell disease
Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation [not related to COVID-19])
Medical condition/factor conferring high risk for progression to severe COVID-19, such as race or ethnicity.
Learn more about high risk medical conditions on CDC.gov
Which patients are NOT eligible for this therapy?
those previously hospitalized due to COVID-19
those who require oxygen therapy due to COVID-19
those who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related co-morbidity
How do I refer a patient for this therapy?
Any New Mexico physician or advanced practice clinician can refer a patient for monoclonal antibody therapy.
Once you have determined that your patient is eligible for treatment:
Download, print, and complete this two-page referral form
Fax the referral form and other required documents, to Presbyterian Infusion Services at 505-563-1015.
Other required documents include:
Fax coversheet from referring provider’s primary practice
Patient demographics (patient name, DOB, address, insurance, primary language)
Copy of most recent clinical encounter (e.g. history and physical, progress note, telephone note, video appointment note)
Copy of positive COVID-19 test result. If a copy of the test result is not available, mitigating reasons must be noted.
PLEASE NOTE: Treatment will not be provided unless positive COVID-19 test result is confirmed.
Providers: If you have questions regarding eligibility of your patient, please call
Where can my patients get this treatment?
Not all Presbyterian regional sites may offer COVID-19 infusion services, or services may be limited to adults only. Please call site to confirm availability and hours of operation.
Questions about the Monoclonal Antibody Therapies?
Para los pacientes
Para los pacientes